Advertisement

Picture Berlin Partner Top News CRIPSR Repairs Immune Cells 650x100px
Organisation › Details

Syncona Partners LLP

Syncona is a leading FTSE250 healthcare company focused on investing in and building global leaders in life science. Syncona’s vision is to deliver transformational treatments to patients in truly innovative areas of healthcare while generating superior returns for shareholders. Its current investment portfolio consists of seven high quality companies in life science and a leading range of fund investments. Syncona seeks to partner with the best, brightest and most ambitious minds in science to build globally competitive businesses. It is an established leader in gene therapy, cell therapy and advanced diagnostics, and focuses on delivering dramatic efficacy for patients in areas of high unmet need. Syncona’s fund investments represent a productively deployed evergreen funding base which enables the business to take a long-term approach to investing in life sciences as its targets the best new opportunities and supports its existing portfolio companies to grow and succeed. Syncona is aligned with two of the premium charitable funders in UK science, the Wellcome Trust, original founder of Syncona, and Cancer Research UK, both of which are significant shareholders in the business. Syncona makes a donation of 0.3% of Net Asset Value to a range of charities each year. *

 

Period Start 2012-08-28 established pred
Period End 2018-06-19 reorganised before
  Group Syncona (Group)
  Today Syncona Ltd. (LON: SYNC)
  Predecessor Wellcome Trust, Sigma project
  Successor Syncona Ltd. (LON: SYNC)
Products Industry venture capital
  Industry 2 LIFE SCIENCES
Persons Person Murphy, Martin (Syncona CEO before Wellcome Trust Sigma project + MVM Life Science Partners + 3i + McKinsey)
  Person 2 Keen, Nigel (Axis-Shield 200606 Chairman)
     
Region Region London, Greater London
  Country United Kingdom (GB)
  Street 215 Euston Road
  City NW1 2BE London
  Tel +44-20-7611-2031
    Address record changed: 2022-03-19
     
Basic data Employees n. a.
  Currency GBP
  Annual sales 200,000,000 (assets, managed 2014-12-16)
     
    * Document for »About Section«: Freeline Therapeutics Ltd.. (6/19/18). "Press Release: Freeline Secures Over £88 Million of Funding". London.
     
   
Record changed: 2021-02-21

Advertisement

Picture Swiss Biotech Association Swiss Biotech Days 2024 SBD24 Basel 650x200px

More documents for Syncona (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture EBD Group World of Partnering Opportunities 650x300px




» top